Loading…
AbbVie Inc. is projected to rise to $293.38 by 2027, a +18% move from its current price of $248.08. ABBV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $244.15 | $248.19 | $252.29 | +0.04% |
| Jul 14 | $242.61 | $248.29 | $254.11 | +0.09% |
| Jul 15 | $241.45 | $248.40 | $255.55 | +0.13% |
| Jul 16 | $240.50 | $248.51 | $256.78 | +0.17% |
| Jul 17 | $239.67 | $248.61 | $257.89 | +0.21% |
| Jul 18 | $238.94 | $248.72 | $258.90 | +0.26% |
| Jul 19 | $238.27 | $248.83 | $259.85 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $238.27 | $248.83 | $259.85 | +0.30% |
| Week 2 | $234.73 | $249.57 | $265.35 | +0.60% |
| Week 3 | $232.22 | $250.32 | $269.84 | +0.90% |
| Week 4 | $230.23 | $251.08 | $273.81 | +1.21% |
| Week 5 | $228.57 | $251.83 | $277.46 | +1.51% |
| Week 6 | $227.14 | $252.59 | $280.88 | +1.82% |
| Week 7 | $225.90 | $253.35 | $284.13 | +2.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbbVie Inc. is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. currently trades at $253.35 per share, with a market capitalization of $447.62B and a rank of 25. The stock sits in a context of bullish technical sentiment, with a 30-day range from $227.05 to $282.70 and a movement framework defined by key levels: support at $208.50 and resistance at $243.14.
The price outlook projects meaningful upside over the coming years, with forecasted averages rising from $253.35 in 2026 toward higher levels in subsequent years.
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 14.2% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 16.4% above — clearing it would confirm fresh momentum.
Key ABBV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABBV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $252.03 | Sell | $250.88 | Sell |
| MA 10 | $253.16 | Sell | $249.23 | Sell |
| MA 20 | $240.43 | Buy | $242.55 | Buy |
| MA 50 | $223.92 | Buy | $230.14 | Buy |
| MA 100 | $219.87 | Buy | $223.91 | Buy |
| MA 200 | $222.79 | Buy | $218.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.34 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 39.23 | Neutral |
| Williams %R (14) | -41.82 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | 5.67 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 58.18 | Neutral |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 20.42 | Buy |
| Ultimate (7,14,28) | 54.77 | Neutral |
| Momentum (10) | 4.94 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 250.13 | Sell |
| ADX (14) | 30.52 | Buy |
| ATR (14) | 3.57 | Info |
The near-term setup shows a bullish tilt, with RSI(14) at 70 and a price path supported by the 50-day simple moving average of $213.88 and the 200-day simple moving average of $221.05. These moving averages frame a constructive backdrop, suggesting room for gains as momentum remains positive. A defined support at $208.50 and resistance at $243.14 provide clear intraday anchors for traders.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $197.38 | $248.08 | $340.20 | 0% | Neutral | |
| $240.27 | $293.38 | $374.54 | +18% | Neutral | |
| $272.01 | $338.37 | $443.65 | +36% | Bullish | |
| $301.47 | $380.81 | $509.93 | +54% | Bullish | |
| $353.03 | $451.95 | $616.09 | +82% | Bullish | |
| $425.28 | $551.10 | $763.12 | +122% | Bullish | |
| $440.26 | $576.96 | $810.28 | +133% | Bullish | |
| $470.26 | $622.77 | $885.94 | +151% | Bullish | |
| $520.55 | $696.21 | $1,002.26 | +181% | Bullish | |
| $523.01 | $706.13 | $1,027.84 | +185% | Bullish | |
| $808.84 | $1,138.99 | $1,737.41 | +359% | Bullish | |
| $1,548.22 | $2,338.20 | $3,823.19 | +843% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $197.38 | $248.08 | $299.55 | +0.00% |
| August 2026 | $220.25 | $257.85 | $308.43 | +3.94% |
| September 2026 | $219.31 | $257.97 | $310.97 | +0.05% |
| October 2026 | $224.25 | $264.86 | $321.37 | +2.67% |
| November 2026 | $232.22 | $275.23 | $335.79 | +3.91% |
| December 2026 | $233.33 | $277.43 | $340.20 | +0.80% |
Click any year to see its month-by-month ABBV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABBV to range from $197.38 to $340.20 through 2026. The $248.08 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABBV price prediction for 2027 points to an average of $293.38 (low $240.27, high $374.54) — a potential gain of +18% on today's $248.08. A consolidation phase looks the most probable path here.
In 2028, ABBV is projected to trade between $272.01 and $443.65, averaging $338.37 — a potential gain of +36% from today's $248.08. That is up +15% on the projected 2027 average. Momentum favours further upside here.
AbbVie Inc.'s 2029 outlook centres on $380.81, within a $301.47 to $509.93 range. That is up +13% on the projected 2028 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ABBV could reach as high as $616.09, with a base case around $451.95 and support toward $353.03 — roughly +82% from $248.08. Momentum favours further upside here.
Expect ABBV to range from $425.28 to $763.12 through 2031. The $551.10 average target implies a +122% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABBV price prediction for 2032 points to an average of $576.96 (low $440.26, high $810.28) — a potential gain of +133% on today's $248.08. Momentum favours further upside here.
In 2033, ABBV is projected to trade between $470.26 and $885.94, averaging $622.77 — a potential gain of +151% from today's $248.08. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
AbbVie Inc.'s 2034 outlook centres on $696.21, within a $520.55 to $1,002.26 range. That is up +12% on the projected 2033 average. That marks a +181% change versus current levels. Momentum favours further upside here.
By 2035, ABBV could reach as high as $1,027.84, with a base case around $706.13 and support toward $523.01 — roughly +185% from $248.08. Buyers look set to stay in control over this stretch.
Expect ABBV to range from $808.84 to $1,737.41 through 2040. The $1,138.99 average target implies a +359% move from current prices. That is up +61% on the projected 2035 average. Momentum favours further upside here.
The ABBV price prediction for 2050 points to an average of $2,338.20 (low $1,548.22, high $3,823.19) — a potential gain of +843% on today's $248.08. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABBV today (≈ 4.030958 ABBV) could be worth
$9,425.17
+$8,425.17 (+843%) by 2050 · US Dollar
Based on the average projected ABBV price of $2,338.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABBVwould be worth at today's price.
$1,000 invested in ABBV on Jul 10, 2025 (≈ 5.128205 ABBV) would be worth
$1,272.21
+$272.21 (+27.2%) today · 1.27× · US Dollar
Based on a ABBV entry price of $195 vs. today's $248.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $261.07 | $950.24 | -5.0% |
| 1 month ago | $224.95 | $1,102.82 | +10.3% |
| 3 months ago | $207.94 | $1,193.04 | +19.3% |
| 6 months ago | $220.04 | $1,127.43 | +12.7% |
| 1 year ago | $195 | $1,272.21 | +27.2% |
| All time (5.0y) ago | $117.91 | $2,103.98 | +110.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABBV forecast.
Our base-case forecast reaches $500.00 around 2031.
Implied market cap at $500.00: $883.4B
The multi-year forecast paints a substantial upside path. In 2026 the average price is projected at $253.35, with a minimum of $197.38 and a maximum of $346.44, yielding a neutral outlook. By 2030 the average is $460.74 and the max is $628.47, with a predicted ROI of 81.9% and a bullish sentiment.
The forecast continues to rise across the decade, with 2040 averaging $1,135.71 and a max of $1,732.96, an estimated ROI of 348.3% and a bullish outlook; and by 2050 the average reaches $2,302.83 with a max of $3,766.23, an estimated ROI of 809% and a bullish sentiment. Notable intermediate milestones include 2031 (avg $555.25, max $769.29, ROI 119.2%), 2032 (avg $576.50, max $810.06, ROI 127.5%), and 2033 (avg $630.67, max $897.61, ROI 148.9%). These figures imply a strong long-run upward trajectory, with higher potential in later years while acknowledging that forecasts are estimates and carry uncertainty.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $460.74 with a min of $359.72 and a max of $628.47; the ROI is 81.9% and sentiment is BULLISH.
Forecasts show rising averages over time, with 2029 at $385.26, 2030 at $460.74 (ROI 81.9%), and 2050 at $2,302.83 (ROI 809%), all with a bullish stance; however, these are estimates and not guarantees.
Yes. The forecasted path includes 2034 with a max of $1,007.81 and 2035 with a max of $1,015.92; later years show even higher max values, including 2040 at $1,732.96 and 2050 at $3,766.23.
For 2026, the min/avg/max are $197.38 / $253.35 / $346.44 respectively, with ROI 0 and a NEUTRAL sentiment.
RSI(14) is 70, with SMA50 at $213.88 and SMA200 at $221.05. Support is at $208.50 and resistance at $243.14, and the 30-day price range spans $227.05 to $282.70.
AbbVie Inc. Community Discussion
0Share your AbbVie Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.